Dihexa is a synthetic peptide derived from angiotensin IV that has captured significant attention in the neuroscience research community. Originally developed at Washington State University, Dihexa has been explored in preclinical models for its potent effects on cognitive function — particularly memory formation and synaptic connectivity. As a small, orally active compound with exceptional blood-brain barrier permeability, Dihexa occupies a unique position among peptides studied for neurological applications.
Research into the Dihexa peptide mechanism centers on its interaction with the hepatocyte growth factor (HGF) and its receptor, the MET proto-oncogene (c-MET). Studies have investigated how this signaling pathway may support the formation of new synaptic connections, a process researchers believe underlies learning and memory consolidation. This guide explores what the scientific literature reveals about Dihexa, how it works, and why it continues to be a subject of active laboratory investigation.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. Dihexa is not approved for human therapeutic use and is intended solely for use in controlled laboratory settings by qualified researchers.
Dihexa - 10MG — Research-Grade Reference Material Dihexa - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
Dihexa - 10MG - Nasal Spray
$100.00$75.00 with 1st order
Selank - 10MG
$45.00$33.75 with 1st order
TB-500 - 5MG
$45.00$33.75 with 1st order
Frequently Asked Questions
What is Dihexa peptide?
Dihexa (also designated N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic oligopeptide derived from angiotensin IV. It was developed at Washington State University and has been studied in preclinical research for its potential to support cognitive function through modulation of the HGF/c-MET signaling pathway.
How does Dihexa work mechanistically?
Research suggests Dihexa acts as a potentiator of hepatocyte growth factor (HGF) at its receptor, c-MET. This interaction has been observed in studies to promote synaptogenesis — the formation of new synaptic connections — in neuronal cell models. Researchers believe this mechanism may underlie observed improvements in cognitive performance in preclinical animal models.
What is the HGF/c-MET pathway and why is it relevant to cognition?
The HGF/c-MET signaling pathway plays a known role in neuronal growth, survival, and synaptic plasticity. Studies have investigated this pathway in the context of learning and memory, with some research suggesting that enhancing HGF/c-MET signaling may support the structural remodeling of synaptic networks associated with memory formation.
Has Dihexa been compared to other nootropic peptides in research?
Dihexa has been compared to brain-derived neurotrophic factor (BDNF) analogues and other neurotrophin-pathway agents in research contexts. Some studies have characterized it as operating through a distinct mechanism from traditional nootropics, making it a unique subject of investigation. Researchers also sometimes study it alongside other neuropeptides such as Semax or Selank, though these operate through different pathways.
Is Dihexa the same as angiotensin IV?
No. Dihexa is a structural analogue of angiotensin IV (Ang IV), modified to improve metabolic stability and central nervous system penetration. While both interact with similar receptor systems, Dihexa was specifically engineered for greater potency and durability in preclinical research settings.
Does Dihexa cross the blood-brain barrier?
Preclinical studies have indicated that Dihexa has high lipophilicity, which is associated with efficient penetration of the blood-brain barrier. This property makes it of particular interest in neurological research, as many peptides have limited CNS access due to their size or polarity.
Where can researchers obtain Dihexa for laboratory use?
Dihexa is available from qualified research peptide suppliers for use in controlled laboratory environments. It is intended exclusively for in vitro and preclinical research by credentialed investigators — not for personal use or human consumption.
Origins and Development of Dihexa
Dihexa was synthesized and characterized by a research team led by Dr. Joseph Harding and Dr. Curt Bhum at Washington State University. The peptide emerged from a line of investigation into the role of angiotensin-related peptides in cognitive processing. Angiotensin IV, a naturally occurring fragment of the renin-angiotensin system, had previously been observed to influence memory and learning in animal models, but its rapid enzymatic degradation and poor CNS penetration limited its research utility.
Dihexa - 10MG — Research-Grade Reference Material Dihexa - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
Dihexa - 10MG - Nasal Spray
$100.00$75.00 with 1st order
Selank - 10MG
$45.00$33.75 with 1st order
TB-500 - 5MG
$45.00$33.75 with 1st order
To address these limitations, researchers engineered Dihexa as a more stable, lipophilic analogue. The resulting compound demonstrated markedly improved half-life and blood-brain barrier permeability in preclinical models, enabling more consistent delivery to neuronal tissue. Its discovery was significant enough to be reported in early studies as potentially millions of times more potent than BDNF in facilitating certain aspects of synaptic connectivity — a claim that generated considerable scientific interest and ongoing scrutiny.
Structural Features That Matter for Research
From a structural standpoint, Dihexa is classified as a small peptidomimetic molecule — meaning it mimics peptide function while having a molecular structure engineered for stability. Its lipophilic modifications allow it to resist degradation by peptidases in the bloodstream and cerebrospinal fluid. These characteristics make it a technically tractable tool for laboratory research, particularly in studies that require sustained CNS exposure over experimental timelines.
The HGF/c-MET Pathway: Core Mechanism of Dihexa Research
The central mechanistic focus of Dihexa research involves the hepatocyte growth factor (HGF) and its receptor tyrosine kinase, c-MET. Although HGF was first identified in the context of liver regeneration, subsequent research has established it as a pleiotropic growth factor with important roles in the central nervous system. The HGF/c-MET signaling axis is expressed throughout the brain and has been implicated in neuronal development, neuroprotection, and synaptic plasticity.
How Dihexa Interacts With This Pathway
Research suggests that Dihexa does not act as a direct agonist of c-MET, but rather as an allosteric potentiator of HGF — meaning it enhances the binding affinity of endogenous HGF for its receptor rather than activating the receptor independently. This distinction is important in pharmacological terms: potentiators typically produce more nuanced, context-dependent effects than full agonists, and may carry a different profile of downstream consequences in research models.
Upon HGF/c-MET activation potentiated by Dihexa, studies have observed downstream signaling through pathways including PI3K/Akt and MAPK/ERK — both of which are associated with neuronal survival, dendritic branching, and synaptic growth. Preclinical cell culture work has demonstrated that these signals can promote the formation of new synaptic contacts (synaptogenesis), a structural process considered fundamental to long-term memory encoding.
Synaptogenesis and Memory: What Preclinical Models Show
In rodent models, Dihexa administration has been associated with measurable improvements in performance on spatial memory tasks, including the Morris Water Maze — a widely used paradigm for assessing hippocampal-dependent learning. Researchers have reported that animals receiving Dihexa demonstrated enhanced retention of learned spatial information compared to control groups, with histological analyses suggesting increased dendritic spine density in hippocampal regions.
These findings align with the hypothesis that HGF/c-MET-mediated synaptogenesis can functionally improve memory encoding in preclinical models. However, researchers note that translating these findings requires further investigation across species and experimental conditions.
Dihexa in the Context of Cognitive Decline Research
One of the primary research applications for Dihexa has been in models of age-related and neurodegeneration-associated cognitive decline. As organisms age, synaptic density in key memory regions — particularly the hippocampus and prefrontal cortex — tends to decrease, a phenomenon associated with declining cognitive performance. Researchers have explored whether HGF/c-MET pathway enhancement via Dihexa may attenuate or partially reverse these synaptic losses in aged animal models.
Early studies reported that aged rats treated with Dihexa showed cognitive performance approaching that of younger control animals on certain memory tasks. These results have generated interest in understanding whether synaptogenic compounds could serve as tools for studying the biology of cognitive aging, independent of therapeutic claims.
Comparison With Other Neurotrophin-Pathway Research Tools
Dihexa has been positioned in some research contexts alongside other neurotrophin-influencing compounds. BDNF (brain-derived neurotrophic factor) itself is the most studied synaptic plasticity factor, but native BDNF has poor CNS delivery characteristics as a research tool. Dihexa’s reported potency relative to BDNF — though figures vary across studies and must be interpreted carefully — makes it a subject of considerable interest for researchers who need CNS-active synaptogenic tools in preclinical settings.
Other neuropeptides studied in cognitive research contexts, such as Semax (an ACTH analogue with BDNF-upregulating properties) and Selank (with anxiolytic and putative nootropic actions), operate through distinct pathways. Dihexa’s HGF/c-MET mechanism is considered mechanistically unique among the peptides currently available for research use.
Semax 10MG for cognitive research →
Pharmacokinetics and Research Considerations
Understanding how Dihexa behaves pharmacokinetically is essential for researchers designing experiments. Its lipophilicity is both a strength and a consideration: while it enables CNS penetration, it also means the compound tends to distribute broadly across tissues. Studies have explored both systemic and direct CNS administration routes in animal models, with each approach yielding different exposure profiles.
Stability and Storage in Laboratory Settings
Dihexa is generally reported to be more resistant to peptidase degradation than native angiotensin IV due to its engineered chemical modifications. For laboratory storage, it is typically maintained as a lyophilized powder under cold, desiccated conditions to preserve integrity. Researchers working with Dihexa should follow standard protocols for peptide reconstitution and short-term storage to ensure compound integrity across experimental timepoints.
Dosing Ranges in Preclinical Literature
Published preclinical literature has explored a range of Dihexa concentrations in rodent models, typically expressed in mg/kg body weight or as nanomolar concentrations in in vitro cell systems. It is important to note that preclinical dosing data does not translate directly to any human application, and these figures are relevant only for informing laboratory research design. Researchers should consult primary literature for specific dosing protocols relevant to their model systems.
Research Landscape: What Remains Unknown
While the early preclinical data on Dihexa is compelling from a mechanistic standpoint, the research field acknowledges several important gaps. The majority of published studies have been conducted in rodent models, and the translation of HGF/c-MET-mediated synaptogenesis to primate or human biology remains an open area of investigation. Additionally, the long-term consequences of sustained c-MET pathway potentiation — including potential oncogenic considerations, given c-MET’s role in some cancer pathways — are subjects that researchers continue to study.
The question of selectivity is also relevant: Dihexa’s effects on non-neuronal tissues expressing c-MET are not fully characterized across all research contexts. These knowledge gaps represent active areas where further preclinical work is warranted before more definitive conclusions can be drawn.
Ongoing Interest in Neuropeptide Stacking Research
Some researchers have explored Dihexa as one component of broader neuropeptide research panels, studying it alongside compounds such as Pinealon (a peptide bioregulator with reported effects on neuronal gene expression) or NAD+ (which supports mitochondrial function and has been studied in neuroenergetics contexts). These multi-compound investigations aim to map potential mechanistic synergies and are conducted entirely within controlled preclinical frameworks.
Where These Fit in Your Research Library
If your laboratory focuses on cognitive and neurological peptide research, Dihexa represents a mechanistically distinct and highly studied compound for investigating HGF/c-MET-mediated synaptogenesis. It pairs well in research panels with other CNS-active peptides:
- Semax — studied for BDNF pathway modulation and neuroprotection in rodent models
- Selank — explored for anxiolytic and cognitive stabilization properties via enkephalin system interactions
- Pinealon — a tripeptide bioregulator investigated for neuronal gene expression and age-related cognitive models
Dihexa 10MG for laboratory research →
Browse the full catalog of research-grade peptides at SourcePeptides.co to build a comprehensive cognitive research toolkit.
Final Takeaway: Why Dihexa Continues to Attract Research Attention
Dihexa occupies a compelling and mechanistically unique position in the landscape of neuropeptide research. Its ability to potentiate the HGF/c-MET signaling pathway — promoting synaptogenesis in preclinical neuronal models — distinguishes it from classical nootropic compounds that primarily target neurotransmitter systems. The early rodent data on memory performance and synaptic density has provided a foundation that researchers continue to build upon, while important questions about long-term effects, tissue selectivity, and cross-species translation remain active areas of inquiry.
For laboratory investigators studying the structural biology of memory, cognitive aging, or neurotrophin signaling, Dihexa represents a valuable and pharmacologically well-characterized research tool. As always, all use of this compound is strictly within the bounds of controlled preclinical research, in accordance with applicable institutional and regulatory guidelines.
Sources & Further Reading
- McCoy et al. — “Identification of a small molecule inhibitor of HGF/c-Met interaction…” — Journal of Pharmacology and Experimental Therapeutics (2013)
- PubMed Search — Dihexa cognitive research studies
- Bhum et al. — “Angiotensin IV and its analogs potently stimulate…” — Neurobiology of Learning and Memory (2012)
- PubMed Search — HGF/c-MET pathway and synaptogenesis
- NIH/PMC — “Hepatocyte growth factor and the developing nervous system” — Molecular Neurobiology
